Diabetes Revolution: Thriving in Today's World

12/07/2023

New obesity meds

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.

11/29/2023

Mounjaro- more weight loss

Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly's Mounjaro than those taking Novo Nordisk's popular rival weight loss drug.

11/28/2023

11/23/2023

Neuropathy, a delimma

The rise in diabetic neuropathy over the last few decades has paralleled the obesity and related diabetes pandemics, one expert says, and neurologists have a role to play in controlling it.

11/23/2023

Diabetes medications

11/13/2023

Diagnosing Diabetes

In the first of a four-part series, Anne Peters, MD, explains why diagnosing diabetes isn't necessarily easy.

11/09/2023

Good news

Tirzepatide, the active ingredient in Eli Lilly’s Zepbound, is already approved under the name Mounjaro for the treatment of type 2 diabetes.

11/07/2023

Insulin facts

A new Cochrane Review based on published and unpublished data finds that unopened insulin can last for up to 6 months and at temperatures up to 25°C (77°F).

11/04/2023

New antiobesity meds

With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are in sight.

10/25/2023

Hypoglycemia facts

Did you know that second-generation basal insulins are associated with lower risk of hypoglycemia in type 2 diabetes?

10/24/2023

Collaborative approach on insulin

Did you know that second-generation basal insulins are associated with lower risk of hypoglycemia in type 2 diabetes?

10/21/2023

Check your knowledge

Test your knowledge on the updated type 2 diabetes practice essentials, including how and when to use them with this quick quiz.